Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMD Receives CAP Accreditation for Cambridge NGS Laboratory

NEW YORK (GenomeWeb) – MolecularMD has received accreditation from the College of American Pathologists for its next-generation sequencing laboratory in Cambridge, Mass.

The accreditation follows CLIA certification of the lab earlier this year. Molecular MD opened the lab in 2012 to complement its RT-PCR and immunohistochemistry laboratory in Portland, Ore.

The company has developed NGS cancer panels on multiple platforms, specializing in tissue- and blood-based assays for retrospective evaluations and prospective clinical trial enrollment.

The NGS laboratory has validated methods and platforms for circulating tumor DNA analysis. It recently validated the Thermo Fisher Ion AmpliSeq Cancer Hotspot Panel v2 for the detection of somatic hotspot mutations with less than 1 percent allele frequency in ctDNA.

The company has also adopted Thermo Fisher's Oncomine Cancer Research panel for the analysis of mutations, copy number alterations, and fusions in cancer genomes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.